Xytide Biotech NZ

Xytide Biotech is a New Zealand-based biotechnology company specializing in the development of a novel class of constrained peptide therapeutics. Spun out from the Ferrier Research Institute at Victoria University of Wellington, the company utilizes its proprietary Xytide platform to engineer peptides with enhanced stability, potency, and cell permeability. Their research focuses on addressing challenging intracellular targets that are typically considered undruggable by small molecules or traditional biologics. Xytide Biotech aims to advance a pipeline of candidates primarily in the fields of oncology, metabolic disorders, and inflammatory diseases. The company is supported by Bridgewest Ventures NZ and the university's commercialization arm, Viclink.